

## PRESS RELEASE



# CytoTools

### Final clinical phase III under way in Europe for *DermaPro*<sup>®</sup>, the lead wound healing product from DermaTools Biotech GmbH

- Application documentation submitted for study in the indication of diabetic foot syndrome
- Strong medical demand due to steadily growing number of diabetic diseases worldwide
- Planned study on up to 300 patients at well-known European centres

Darmstadt, 16 January 2013 – DermaTools Biotech GmbH, a subsidiary of CytoTools AG, has launched clinical phase III of its wound healing product *DermaPro*<sup>®</sup> in Europe. The relevant application documents have been filed with the German Federal Institute for Drugs and Medical Devices (BfArM). This study should provide definitive proof of the product's effectiveness and tolerance levels in patients with diabetic foot syndrome. Following the outstanding results of the previous European and Indian studies, development has now also reached the final phase in Europe. If the results are consistent with the previous excellent ones, European certification of *DermaPro*<sup>®</sup> will follow straightaway. It will also meet the certification requirements for other important non-European markets.

Chronic and poorly healing wounds on legs and feet, which occur in particular in diabetic patients (diabetic foot syndrome), represent a global medical problem which is steadily worsening and needs to be taken very seriously. According to current research by the International Diabetes Federation, the total number of diabetes sufferers worldwide in 2012 passed the 370 million mark. There are well over 5 million diabetics in Germany alone. "Up to 20% of all diabetics develop diabetic foot as a result of circulatory disorders and vascular constriction, often ending in amputation. This highlights the pressing need for a product that can help heal these difficult wounds." Dr. Dirk Kaiser, Managing Director of Derma Tools Biotech GmbH, points out the enormous potential of *DermaPro*<sup>®</sup>, to which treatment offers no alternatives.

As part of the indication-specific trial being conducted in Europe, up to 300 patients will be treated at 30 or so well-known European diabetes specialist centres, completing another major step on the road to the certification of *DermaPro*<sup>®</sup>. "This data will then be used to apply for certification in other important pharma markets," as Dr. Dirk Kaiser stated.

*This release contains specific future-oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.*

**CytoTools AG**, previously CytoTools GmbH, is a technology and holding company which holds the following shares in its subsidiaries which carry out product development in the pharmaceutical and medical products field: approx. 60% in DermaTools Biotech GmbH (therapy field dermatology, urology) and 46% in CytoPharma GmbH (therapy field cardiovascular disease, cancer). The complete know-how is protected by corresponding basic patents which are maintained worldwide by CytoTools AG and transferred to the subsidiary companies in the form of exclusive licenses.

## ***PRESS RELEASE***



# CytoTools

### **Contact:**

CytoTools AG  
Dr. Mark Andre Freyberg  
Klappacher Str. 126  
64285 Darmstadt, Germany  
Tel.: +49-6151-95158-12  
Fax: +49-6151-95158-13  
E-Mail: [freyberg@cytotools.de](mailto:freyberg@cytotools.de)

### **Press contact:**

cometis AG  
Ulrich Wiehle  
Unter den Eichen 7  
65195 Wiesbaden, Germany  
Tel.: +49-611-205855-11  
Fax: +49-611-205855-66  
E-Mail: [wiehle@cometis.de](mailto:wiehle@cometis.de)